Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children with Growth Hormone Deficiency.

Trial Profile

Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children with Growth Hormone Deficiency.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Somavaratan (Primary)
  • Indications Growth disorders; Somatotropin deficiency
  • Focus Registrational; Therapeutic Use
  • Acronyms VELOCITY
  • Sponsors Versartis
  • Most Recent Events

    • 22 May 2017 Data from this trial were presented during the 19th European Congress of Endocrinology (ECE), as reported in a Versartis media release.
    • 03 Apr 2017 According to a Versartis Inc. media release, based on this study poster was presented at the Endocrine Society's 99th Annual Meeting & Expo (ENDO 2017).
    • 03 Apr 2017 According to a Versartis media release, data from this trial are expected in September 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top